Navigation Links
R&J Public Relations Named Agency of Record for Aerocrine, Inc.
Date:1/25/2011

BRIDGEWATER, N.J., Jan. 25, 2011 /PRNewswire/ -- Aerocrine, Inc., an innovative medical technology company focused on the treatment of patients with inflamed airways, has selected R&J Public Relations, LLC of Bridgewater, N.J., as its public relations agency of record.  R&J will conduct strategic public relations for the Aerocrine brand; most immediately surrounding the NIOX MINO®, the first and only hand-held device available to measure exhaled nitric oxide (eNO) to aid in asthma management in the United States.

For the first time ever, The NIOX MINO provides doctors the ability to more effectively diagnose, monitor and optimize therapy for individuals suffering from inflammatory airway diseases through one easy-to-use device.  This ground-breaking technology helps eliminate the uncertainties that contribute to asthma morbidity and mortality, including incorrect diagnosis, patient adherence issues, and identifying those patients that will be responsive to treatment.

"Our comprehensive experience and strong presence in the healthcare market space combined with our aggressive and proactive consumer and media relations practices will provide Aerocrine with the leverage they need to elevate their innovative brand and products," said Scott Marioni, Executive Vice President of R&J Public Relations.  "R&J is confident that our strategic public relations will significantly increase the awareness of the Aerocrine brand and NIOX MINO while positioning eNO testing as a standard for patients with asthmatic symptoms."

The founders of Aerocrine originated from the Karolinska Institute in Sweden where they first discovered the significant tie between nitric oxide (NO) and inflammation.  Aerocrine used this discovery as a basis for creating products that assist in the management and care of people afflicted with varying airway inflammatory diseases.

R&J's main objective is to promptly elevate Aerocrine's brand through its established world-wide reputation, and further the awareness of Aerocrine's NIOX MINO products among allergists, pulmonologists, and potential patients. Through a decisive, long-term plan, combined with steadfast public and media relations efforts, R&J will support Aerocrine's growth and product-specific goal.

About Aerocrine

Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in the technology to monitor and manage airway inflammation, Aerocrine markets NIOX® Flex and NIOX MINO®. Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June 2007. More information can be found online at www.aerocrine.com.

About R&J Public Relations

R&J Public Relations, LLC is a full-service public relations firm that consistently achieves superior results for a strong and diverse client base that ranges from divisions of large, multi-national conglomerates to regional market leaders.  Based in Bridgewater, N.J., with an office in Manhattan, the company has become one of the most respected, admired and prestigious PR agencies in the Greater New York/New Jersey region.  R&J has earned numerous awards for its strategic communications programs and was named a "Top Place to Work in PR" by PR News in 2010. For more information on R&J Public Relations, please visit www.randjpr.com.


'/>"/>
SOURCE R&J Public Relations, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmasset Prices Public Offering of Common Stock
2. Pharmasset Announces Proposed Public Offering of Common Stock
3. Pharmacists Offer Recommendations to Guide Public Through Cold and Flu Season
4. American Scientific Resources, Inc. Announces S-1 Registration Statement Effective; Commences Public Reporting Requirements
5. Syndax Announces Publication of Entinostat NSCLC Data in Cancer Research
6. FDA Warns Public of Continued Extortion Scam By FDA Impersonators
7. Amarin Prices Public Offering of American Depositary Shares
8. Dr. Marianne T. Sweetser Recognized by Strathmores Whos Who Worldwide Publication
9. HeartWare International, Inc. Announces Completion of Concurrent Public Offerings of Convertible Senior Notes and Common Stock
10. Bionovo Announces Publication Describing How Metabolic Adaptability Contributes to the Metastasis of Tumors
11. Generex Announces Publication of New Positive Generex Oral-lyn™ Data in Peer-Reviewed Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... 27, 2017 Now in its seventh ... that are most successful at developing and commercialising innovation. ... The Index ... same molecule to two different companies in early phase, which ... systematic, objective analysis of each company,s performance between 2011 and 2016, the ...
(Date:2/27/2017)... -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today ... as President and Chief Executive Officer (CEO) and member of ... succeeds Richard Love , interim President and CEO who ... Dr. Craig has over 20 years of experience in hematology, ... Europe . "On behalf of CTI ...
(Date:2/27/2017)... , Feb 27, 2017 The ... by NATO for use at the security level RESTRICTED. The ... the NATO organization for the communication of classified information. ... Sectra and ... with an eavesdrop-secure smartphone solution. Sectra Tiger/R is developed by ...
Breaking Medicine Technology:
(Date:2/27/2017)... , ... February 27, 2017 , ... Robert E. Burke, ... medical group. But his impoverished upbringing and life experiences could have led him down ... Physician: Insightful and Inspirational Tales of Parenting, Perseverance and Pediatrics,” Dr. Burke shares a ...
(Date:2/27/2017)... TN (PRWEB) , ... February 27, 2017 , ... The ... Clayton went to work for a company involved in the underground testing of nuclear ... In “Dying for Answers: Expendable Workers of the Cold War Nuclear Testing,” Clayton exposes ...
(Date:2/27/2017)... , ... February 27, 2017 , ... ... an overview on laser diffraction analysis as a tool to characterize particle size ... and potential to obtain improved results and novel scientific findings. It describes methods ...
(Date:2/27/2017)... TX (PRWEB) , ... February 27, 2017 , ... ... 75,000 customer threshold mark last week. In addition, Discount Power's RCE (Residential Customer ... Energy LLC in March 2014. The company had 800 customers and 2,250 RCEs ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair ... to announce an upgrade to the company's Yelp listing. Bay Area residents struggling ... as diverse as Platelet Rich Plasma (PRP) therapy, hair transplantation techniques such as ...
Breaking Medicine News(10 mins):